Genetic biomarker for cancer immunotherapy

Science

Volumn 357, Issue 6349, 2017, Pages 358-

  Goswami, Sangeeta ^a   Sharma, Padmanee ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CELL SURFACE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; GENETIC MARKER;

ANTIBODY; ANTIGEN; BIOMARKER; CANCER; CELLS AND CELL COMPONENTS; DNA; GENETIC MARKER; GENETICS; IMMUNE SYSTEM; PATHOGEN; PROTEIN; TUMOR;

ANTIGEN PRESENTING CELL; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; DNA DAMAGE RESPONSE; GENE MUTATION; GENETIC MARKER; HUMAN; MALIGNANT NEOPLASM; MISMATCH REPAIR; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; IMMUNOTHERAPY; NEOPLASM;

GENETIC MARKERS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 85026284819     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aao1894     Document Type: Short Survey

References (14)

1. T. L. Walunas et al., Immunity 1, 405 (1994).
2. D. R. Leach, M. F. Krummel, J. P. Allison, Science 271, 1734 (1996).
3. P. Sharma, J. P. Allison, Science 348, 56 (2015).
4. D. T. Le et al., Science 357, 409 (2017).
5. B. Vogelstein et al., Science 339, 1546 (2013).
6. N. H. Segal et al., Cancer Res. 68, 889 (2008).
7. T. N. Schumacher, R. D. Schreiber, Science 348, 69 (2015).
8. N. A. Rizvi et al., Science 348, 124 (2015).
9. A. Snyder et al., N. Engl. J. Med. 371, 2189 (2014).
10. E. M. Van Allen et al., Science 350, 207 (2015).
11. S. L. Topalian et al., N. Engl. J. Med. 366, 2443 (2012).
12. K. W. Kinzler, B. Vogelstein, Cell 87, 159 (1996).
13. J. R. Eshleman et al., Oncogene 10, 33 (1995).
14. D. T. Le et al., N. Engl. J. Med. 372, 2509 (2015).